Bristol Myers Squibb has agreed to pay $13.1 billion for MyoKardia, a clinical stage biopharmaceutical company focused on developing treatments for heart disease, the companies said Monday, in a deal built by Goodwin Public M&A and Life Sciences teams led by Stuart Cable, Lisa Haddad, Mitchell Bloom, Mike Patrone and Maggie Wong, with assistance from Andrea Murino, Kirby Lewis, Sarah Bock, Robert Crawford, Stephanie Philbin, Daniel Karelitz, Michael Jones, Jennifer Fay, Natalie Martirossian, Jackie Klosek, Grace Wirth, Cecelia Lockner, Chukwudi Udeogalanya, Hayden Hutton, William Stanton, Jordan Howe, Matthew Wheatley, Andre Amorim, Nicole Spiteri and Sophie Duffy. Read the Law360 article here.
Related Professionals
- Stuart M. Cable
- Lisa R. Haddad
- Mitchell S. Bloom
- Michael R. Patrone
- Maggie L. Wong
- Andrea Agathoklis Murino
- Kirby H. Lewis
- Sarah M. Bock
- Robert M. Crawford, Jr.
- Stephanie Philbin
- Daniel S. Karelitz
- Michael T. Jones
- Jennifer Merrigan Fay
- Natalie Martirossian
- Jacqueline Klosek
- Grace L. Wirth
- Cecelia Lockner
- Chukwudi Udeogalanya
- William Stanton
- Jordan Howe
- Matthew S. Wheatley
- Andre Amorim
- Nicole Spiteri
- Sophie Duffy